Annals of Hepato-Biliary-Pancreatic Surgery

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2508-5859   pISSN 2508-5778

Table. 2.

Table. 2.

Selected clinical trials of neoadyuvant therapy for resectable pancreatic cancer

Author Year N Neoadjuvant regimen Resected (%) Resected 0 (%) Survival Clinical trial
Chemoradiotherapy
*Pisters et al.47 2002 35 CCRT
Paclitaxel+RT (30 Gy)+IORT
57 68 28% (3-yr)
19 (mo) R
Phase II
Talamonti et al.48 2006 20 CCRT
Gem+RT (36 Gy)
85 94 26 (mo) R Phase II
*Evans et al.43 2008 86 CCRT
Gem, 400 mg/m2 weekly×7+RT, 30 Gy
74 89 27% (5-yr)
34 (mo) R
Phase II
Chemottherapy followed by chemoradiation
*Varadhachary et al.44 2008 90 Gem, 750 mg/m2+cisplatin 30 mg/m2 → CCRT
Gem, 400 mg/m2+RT, 30 Gy
66 96 31 (mo) R Phase II
Christians et al.45 2016 69 Chemotherapy (various) and chemoradiation 87 97 31.5 (mo)
44, 9 (CT)
Retrospective
Chemotherapy alone
Palmer et al.49 2007 50 Gemcitabine vs Gemcitabine+Cisplatino Gem: 38
Gem+Cis: 70
Gem: 75
Gem+Cis: 75
Gem: 42 (1-yr) Phase II
Heinrich et al.50 2008 28 Gem, 1 g/m2, Cis, 50 mg/m2 93 80 26.5 (mo) Phase II
O’Reilly et al.51 2014 38 Gem, 1 g/m2, Oxa, 80 71 mg/m2 71 74 63% (1, 5-yr)
27.2 (mo)
Phase II

*MDACC Clinical trials Phase II

R, resected; Gem, gemcitabine; Cis, cisplatino; Oxa, oxaliplatino; Gy, gray; IORT, intraoperative radiotherapy; mo, months; yr, years, CCRT, concurrent chemoradiation; RT, radiotherapy; CT, complete treatment

Ann Hepatobiliary Pancreat Surg 2021;25:179-91 https://doi.org/10.14701/ahbps.2021.25.2.179
© 2021 Ann Hepatobiliary Pancreat Surg